Novo’s CagriSema drives more than 20% weight loss at lower doses
Novo Nordisk presented new data at ObesityWeek showing that lower doses of its next-gen obesity drug CagriSema achieved over 20% weight loss in a Phase 3 trial. This development helps rebuild confidence as the company awaits a crucial FDA decision by the end of the year, following earlier investor disappointments.

Original image temporarily unavailable
Clinical Trial Results
Novo Nordisk reported data from the Phase 3 REDEFINE 9 trial at the ObesityWeek 2026 conference. Patients receiving weekly doses of 1 mg and 1.7 mg of CagriSema lost 21% and 20.7% of their body weight, respectively, at week 68. These findings demonstrate that meaningful efficacy can be achieved below the previously studied highest dose.
Background and Market Context
CagriSema combines the amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide. Earlier data from the REDEFINE 1 trial showed 22.7% weight loss at higher doses, which initially disappointed investors who had expected even higher figures. Despite previous setbacks, including failing to beat Eli Lilly’s Zepbound in a head-to-head test, Novo Nordisk continues to position the drug as a major next-generation therapy.
Regulatory Outlook and Tolerability
The latest findings form part of a broader data presentation as the drug awaits a U.S. FDA decision expected by the end of 2026. Analysts noted that tolerability remained consistent with previous studies, showing common side effects such as nausea and vomiting, while the company prepares to leverage its extensive clinical data to enter the market.
View selection rationale
Importance 83/100
About this brief
- Content type
- News summary
- Source type
- Publisher report
- Original source
- BioSpace Drug Development ↗
- Source published
- Process
- AI-assisted discovery, translation, summarisation, classification and scoring; standards and corrections are maintained by the editorial desk.
- Verification
- The original URL and publication metadata are retained. This brief is not independently fact-checked unless explicitly stated.
- Published by
- Polyemergence Editorial Desk · PolyEmergence Pte Ltd.
- Conflict disclosure
- No financial or commercial conflict declared.

